A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.
Copyright © 2024 | WordPress Theme by MH Themes